in this description a number of documents are cited . the disclosed content of these documents , including instructions of the manufacturer , is hereby incorporated by reference . in the examples “ v / v ” denotes volume percentage and “ w / v ” denotes weight percentage . piiicp was produced in the form of inclusion bodies in e . coli ( burchardt 1998 ). the cell pellets from three 200 ml cell cultures were resuspended in 24 ml 50 mm tris - hcl ( ph 8 . 0 ) 1 m nacl , frozen over night at 20 ° c . and centrifuged at 5 , 000 g for 10 minutes after thawing . 4 . 8 ml of the same buffer were added to the precipitate and 4 . 8 ml of a 25 mm tris - hcl ( ph 8 . 0 ), 5 mg / ml lysozyme as well as 4 . 8 ml of a 0 . 5 m edta solution ( ph 8 . 0 ) were added . after 1 hour of incubation at 37 ° c . the bacteria cells were disintegrated by ultrasonification . subsequently , 12 ml of 10 % triton - x - 100 , 1 mm edta , dissolved in 50 mm tris hcl ( ph 8 . 0 ), were added and after 30 min of incubation the mixture was centrifuged at 5 , 000 g for 10 minutes . the unsoluable fraction was dissolved by ultrasonification in 24 ml 5 % triton - x - 100 , dissolved in 50 mm tris - hcl ( ph 8 . 0 ), incubated at 37 ° c . one more time and was again centrifuged at 5 , 000 g for 10 minutes . the triton extraction was repeated once to remove the membrane lipids . subsequently , the pellet was dissolved by ultrasonification in 24 ml 1 m urea , 1 mm edta , dissolved in 50 mm tris hcl ( ph 8 . 0 ) and centrifuged again after 30 minutes of incubation ( 5 , 000 g , 10 min ). the pellet almost entirely consisted of almost pure piiicp in the form of inclusion bodies . the protein could be dissolved in 6 m urea , in turn dissolved in 50 mm tris - hcl ( ph 8 . 0 ). when the sample was centrifuged for 30 minutes at 15 , 800 g , the inclusion body protein remained in the supernatant . as an example , recombinant human piiicp4 . 1 was renatured , the production of which was described in burchardt , 1998 , and in the patents : an immunoassay for procollagen - iii - c - terminal propeptide ( wo 99 / 24835a2 and ep00988964a1 ). furthermore , recombinant human piiinp 4 . 5 . 2 was renatured , the production of which was described in the patent : monoclonal antibody and assay for detecting piiinp ( wo 99 / 61477a2 ). finally , recombinant murine piiinp , the production of which was described in kauschke , 1999 , was renatured using the method described below . however , the method is not limited to the renaturation of these exemplary propeptides , but is suitable for the renaturation of other procollagen propeptides and similar compounds . collagen α 1 ( iii ) propeptides can be dissolved in 6 m urea buffer . in a limited dilution step the buffer conditions were abruptly altered for the proteins . a redox system present in the buffer facilitated the formation of disulfide bridges . to this effect , the protein solution was added dropwise to a surplus of ice - cold limited dilution - buffer while being gently shaken . this solution was stored over night at 4 ° c . all dialysis steps were performed at 4 ° c . at every step the dialysis was performed for at least three hours and against a one - hundredfold buffer volume . the limited dilution solution was transferred into a tube of suitable pore size and dialyzed against the dialysis buffer . in the following dialysis steps the l - arginine concentration was lowered to 100 mm , subsequently a buffer without l - arginine was used . in addition , the fourth buffer was lacking the glutathione redox system . the final buffer was chosen according to the intended use . for in vivo experiments , for example , it consisted of 10 mm trizma - base , ph 7 . 4 , 145 mm nacl . the dialysate was finally stored at 4 ° c . piiicp - plate - elisa : the determination of piiicp concentrations in biological samples was carried out with a sandwich elisa assay . two monoclonal anti - piiicp antibodies were used ( burchardt , 1998 ). as a catching antibody , antibody 48b14 ( burchardt , 1998 ) was immobilized on an elisa plate at a concentration of 5 μg / ml . after blocking free unspecific binding sites on the plate by incubation with a 3 % ( v / v ) bsa solution , biological samples or buffered solutions with known piiicp concentrations were added together with a known concentration of a fitc - labelled secondary antibody ( 48d19 ) ( burchardt , 1998 ) for 30 minutes to the immobilized secondary antibody . remaining free piiicp antigen and free secondary antibody were subsequently removed by washing steps and the amount of bound , labelled secondary antibody was determined . the aforementioned antibodies can be replaced by other anti - piiicp antibody couples that can be produced according to commonly used practices . the measured in vivo concentrations in human serum were for the most part below the limit of detection ( below 0 . 5 ng / ml , see the patent application : an immunoassay for procollagen - iii - c - terminal propeptide ( wo 99 / 24835a2 and ep00988964a1 )). these results are almost an order of magnitude below the phsysiological piiinp concentrations in human serum . animal experiment : fastened sprague - dawley rats with a body weight of approximately 300 g were anaesthetized by intraperitoneal administration of trapanal at 100 mg / kg body weight . fluids or dilutions of the substances were applied through a catheter placed into the jugular vein . the measurement of the blood pressure as well as the drawing of blood were performed via a femoral artery catheter . to facilitate spontaneous breathing the tracheae of the animals were canalized . during the experiments the animals received infrared heat radiation . after initiation of the surgical procedures , the animals received 5 ml of physiological salt solution per kg body weight as a bolus to compensate for the loss of blood . after a recovery period of 15 minutes , the substance dilutions in physiological buffer ( 10 mm trizma - base , ph 7 . 4 , 145 mm nacl ) were administered for 2 hours by continuous infusion of renatured piiicp4 . 1 ( burchardt , 1998 ) at a flow rate of 100 μl per kg body weight and minute ( the piiicp4 . 1 concentration in the infusion solution was . approximately 150 μg / ml ). blood samples were drawn after 2 min , 60 min , 115 min , 150 min , 180 min and 225 min after the start of the infusion . this was paralleled by a recording of the blood pressure . at each time point 400 μl of blood were drawn and immediately 20 μl of heparin ( 250 ie / ml ) were added , the sample was centrifuged at high speed and the plasma was stored at 20 ° c . until testing . after the experiment the experimental animals were sacrifized by application of a kcl solution . the pharmacokinetic parameters were determined subsequent to the piiicp concentration measurements in the samples . the terminal half life time was determined as approximately 80 minutes . in the terminal area of the curve approximately 6 . 1 % of the total area were under the curve . the distribution volume in the terminal phase was at approximately 7 . 4 l / kg and the rate of elimination was determined at approximately 6 . 3 l / h / kg ( see fig2 ). the biological efficacy of the compounds can be demonstrated in cell culture assays and in vivo . for example , after addition of the inhibitors to human cell lines , a drop in the concentration of free α 1 ( iii ) propeptide in the supernatant can be measured because the peptide is released by the enzymatic activity of pcp . to measure piiicp concentrations in the supernatant a recently established assay can be used ( burchardt , 1997 , and patent application : an immunoassay for procollagen - iii - c - terminal propeptide ( wo 99 / 24835a2 and ep00988964a1 )). in this patent the biological efficacy of piiicp4 . 1 ( production described in burchardt , 1998 , and in the patents : an immunoassay for procollagen - iii - c - terminal propeptide ( wo 99 / 24835a2 and ep00988964a1 ), purification and renaturation described above in this patent as an example ); of piiinp4 . 5 . 2 ( production described in the patent : monoclonal antibody and assay for detecting piiinp ( wo 99 / 61477a2 ), renaturation described above in this patent as an example ) and of murine recombinant piiinp ( production described by kauschke , 1999 , renaturation described above in this patent as an example ) are described as examples in the model of the ccl 4 - induced liver fibrosis of the mouse . for piiicp the antifibrotic effect of 3 different doses of this compound in this animal model is described as an example . depending on the organ manifestation or the kind of fibrotic damage animal models with other fibrosis manifestations , for example in the heart , in the kidney , in the lungs , in the skin , or in other organs can be used . in the example of the ccl 4 - induced liver fibrosis of the mouse the reduction of the collagen deposition brought about by piiicp and piiinp is described by quantitative morphometry . it can also be carried out by determination of the hydroxyprolin content of the fibrotic organs or by quantitative morphometry ( kauschke , 1999 ). in addition , the organ - protective effective effect of piiicp and piiinp by reduction of cell damage is described in the example , as determined by measurement of the activities of intracellular marker enzymes ( e . g . gidh ). the measurement of the organ - protective effect can also be carried out in a different way , for example by measurement of inhibition of the extent of apoptosis or necrosis or such . animal experiments : the experimental animals received 0 . 2 ml per 100 g body weight of a mixture of ccl 4 and mineral oil in a ratio of 1 : 8 twice per week . the substance was administered by daily intraperitoneal application of 0 . 5 ml of a dilution of the substance . the fibrosis - and the intact - controls received a buffer control solution without procollagen propeptides . the animals had free access to standard diet and water during the whole experiment . the body weight of the animals was measured at the beginning and at the end of the experiment . upon termination of the experiment the wet weight of the liver was determined , the liver was portioned for the subsequent experiments and immediately shock - frozen in liquid nitrogen . it was stored until use at 80 ° c . in addition , plasma samples were drawn from the experimental animals to determine clinical chemistry parameters with them . total collagen staining with sirius red / fast green : 14 μm frozen sections were dried over night . after a 10 minute treatment with a 10 % ( v / v ) formaldehyde solution the slices were washed twice for 5 minutes with h 2 o dest ., respectively . the picrosirius red staining was carried out for 30 minutes at room temperature in a 0 . 1 % ( w / v ) sirius red solution in saturated picric acid ( per 400 ml a pbs tablet and 10 ml of concentrated acidic acid were added ). the sections were again washed with h 2 o dest . twice and subsequently stained in a 0 . 1 % ( w / v ) fast green solution in saturated picric acid ( per 400 ml a pbs tablet and 10 ml of concentrated acidic acid were added ). the unstaining and dehydratization steps consisted of a sequence of washing steps : 10 seconds h 2 o dest ., 10 seconds 70 % ( v / v ) ethanol , a minute 80 % ( v / v ) and 90 % ( v / v ) ethanol , respectively , three times with pure ethanol for two minutes , respectively . before they were covered with the leica cv mount , the sections were washed three times in xylol for 5 minutes . total rna preparation from tissue : approximately 20 mg of tissue were pulverized in liquid nitrogen and transferred into an eppendorf tube . 600 μl of rlt buffer ( with 0 . 1 % ( v / v ) β - mercaptoethanol ) were added to the powdered tissue , mixed to homogeneity , and the mixture was applied on a qiashredder column . the column was centrifuged at 18 , 000 g and 4 ° c . for 2 minutes . the retained solid constituents were discarded , and the flow through was further used . the subsequent processing steps were carried out with the rneasy total rna kit ( qiagen , hilden ) according to the manufacturer &# 39 ; s recommendations . the elution steps was carried out with 35 μl of rnase - free h 2 o . the rna content of each preparation was determined directly thereafter in an aliquot , a further aliquot was examined for the integrity of the obtained rna bands using an rna formaldehyde agarose gel . the samples were stored at 80 ° c . until use . cdna synthesis from total rna : the synthesis of cdna from the prepared total rna samples was performed with the superscript preamplification system according to the manufacturer &# 39 ; s ( gibco brl ) recommendations in all cases . all working steps were carried out on ice . in all cases , 1 μg of total rna and master mixes were used . before the reverse transcription potentially present impurities consisting of genomic dna were removed from all samples by digestion with dnase i . for this purpose 1 μg of total rna solution was brought up to a volume of 8 μl with rnase - free water , 1 μl of dnase i solution ( superscript kit ) and 1 μl of 10 × buffer were added and the digest was incubated for 10 minutes at room temperature . the dnase i digest was stopped by the addition of 1 μl of 25 mm edta solution and subsequent incubation ( 10 minutes at 65 ° c .). the whole volume was used in the cdna synthesis . subsequent to the cdna synthesis the volume was brought up to 100 μl total volume with dnase - free water and stored at 80 ° c . until use . in all cdna synthesis procedures , controls without the addition of reverse transcriptase were carried out randomly to check for contaminations consisting of genomic dna . determination of mrna concentrations by a taqman pcr analysis : the determination of specific mrna concentrations was carried out by a taqman analysis . during the pcr reaction a specific hybridizing fluorescent probe is cleaved by the exonuclease activity of the taq polymerase — and the resulting fluorescent signal is measured in real time . the results are presented as the number of cycles when the measured specific fluorescent signal exceeds the threshold value for the first time . smaller ct values indicate that a higher specific mrna concentration had been present in the original sample . maximally achievable is a doubling of the amount of product during each cycle . by choosing suitable primers and probes , and a small length of the amplified sequence , approximately a doubling of the amount of product can be assumed in each pcr cycle during the exponential phase of the reaction . consequently , using the measured differences in the ct values , differences in the mrna concentrations of the respective transcript in the original sample can be calculated after calibration . thus , a calibrated difference of 3 ct units means that the mrna concentrations of this transcript are differing from the reference samples by a factor of 8 (= 23 ) when the assumption of a doubling of the amount of product during each pcr cycle is valid . with regard to the mrna concentrations , all measured mrna concentrations were calibrated based on the respective hprt mrna concentration . for the hprt mrna concentration it was possible to show that it remains unaltered during the course of a fibrotic disease and that hprt can be used as a standard , meaning as a reference level . all primers and probes were so chosen , with respect to their localization on the gene and to the expected amplification product , that a doubling of the concentration of the product in each cycle was to be expected in the course of a taqman pcr reaction . these assumptions were checked by control experiments before and verified . the primers and the 6 - fam - labeled probes were all present at concentrations of 100 μm . to prevent variability between the different incubations master mixes were used in all cases and every incubation was carried out at least in duplicate . determinations of every single transcript were carried out for all samples on the same plate . in all experiments , control experiments without template or without previous reverse transcription were carried out . all work was performed on ice . the master mix contained 12 . 5 μl of the taqman universal master mix ( roche ), 7 . 5 μl of the primer - probe - mix ( 1 μm with respect to each primer and 0 . 5 μm probe in dnase / rnase - free water ) as well as 3 . 75 μl dnase / rnase - free water . per determination , 2 . 5 μl cdna solution were pipetted into 96 well plates with optical lids and mixed with 22 . 5 μl of the master mix . the plates were centrifuged for 1 minute at 500 g and 4 ° c . the program of the taqman pr reaction encompassed a heating phase of 2 minutes at 50 ° c ., a 10 minute denaturing step at 95 ° c . as well as 40 cycles with a denaturing step at 95 ° c . for 15 seconds and a combined one minute annealing / expansion step at 60 ° c . within the cycles , the fluorescence of the liberated fluorescent probe was measured automatically at the time point of the denaturation step . the evaluation was carried out with the abi prism sequence detection software . the baseline was set at the mean of cycles 3 and 15 , the threshold was 0 . 04 . effects of the infusion of procollagen ( iii ) propeptides in the chronic i . p . experiment in the mouse ccl 4 model : to investigate the effect of the recombinantly produced procollagen α 1 ( iii ) propeptides on the formation of an experimentally induced liver fibrosis groups of 10 mice were treated with ccl 4 only or with protein solutions at concentrations of 500 μg / ml , respectively . in addition , one group received buffer control solution only ( intact control ). as therapeutic recombinant proteins , human piiicp4 . 1 ( production described in burchardt , 1998 , and in the patent applications : an immunoassay for procollagen - iii - c - terminal propeptide ( wo 99 / 24835a2 and ep00988964a1 )), purification and renaturation described above in this patent application as an example ); complete human piiinp4 . 5 . 2 ( production described in the patent : monoclonal antibody and assay for detecting piiinp ( wo 99 / 61477a2 ); renaturation described above in this patent as an example ); and murine piiinp containing 18 amino acid residues of the prosequence ( designated m1 , production described by kauschke , 1999 , renaturation described above in this patent application as an example ) were used . at the end of the treatment the dissolved piiicp in the infusion solution was not degraded in all cases . this was demonstrated with an sds page gel . in all animals , the relative collagen area with respect to the total area was determined morphometrically in liver sections as well as the gidh activity in the serum and the mrna concentration of selected transcripts by a taqman analysis . the proteins were well tolerated by the animals over the studied time period in the concentrations used . there were no pathologic signs , furthermore an increased mortality did not occur . the morphometrically determined relative collagen area with respect to the total area , as determined by automated analysis of the sirius red - stained area , showed the highest values in the fibrosis control group ( kauschke , 1999 ). in the treatment groups the relative collagen area with respect to the total area was significantly reduced in all cases ( fig3 a ). with piiicp4 . 1 , to 71 % of the fibrosis control ( p & lt ; 0 . 04 ); with piiinp4 . 5 . 2 to 63 % of the fibrosis control ( p & lt ; 0 . 01 ); and with m1 to 68 % of the fibrosis control ( p & lt ; 0 . 02 ). when the ctgf mrna concentrations in the liver are regarded , a significant reduction in concentration in the treatment groups in comparison to the fibrosis control was observed ( fig3 b ). the differences were approximately + 1 . 9 δ ct - units ( piiicp4 . 1 , p & lt ; 0 . 001 ), approximately + 1 . 5 δ ct - units ( piiinp4 . 5 . 2 , p & lt ; 0 . 01 ), and approximately + 1 . 2 δ ct - units ( m1 , p & lt ; 0 . 02 ). the gidh serum activity was also reduced in all treatment groups in comparison to the fibrosis control ( table 1 ) ( kauschke 1999 ). the serum activities were 17 % ( piiicp 4 . 1 ) or 11 % ( piiinp4 . 5 . 2 , m1 ), respectively , lower than in the fibrosis control . due to individual variations the differences did not reach the level of significance ( p & lt ; 0 . 05 ) in any case . in all cases with ccl 4 application a reduction in body weight ( table 1 ) was observed . differences between the treatment groups and the fibrosis control were not observed . the relative liver weight was above the intact controls in all ccl 4 groups . treated animals tended to present with slightly higher relative liver weights in comparison to the fibrosis control . the absolute liver weights were not significantly different among the groups ( table 1 ). the mrna concentrations of the transcripts for collagens type iii and type i , tgf β 1 ( table 1 ) as well as for lysyl oxidase , mmp - 1 , pai - 1 , and tenascin ( data not shown ) revealed no significant differences between the fibrosis control group and the treatment groups receiving the procollagen α 1 ( iii ) propeptide applications . more detailed studies on the in vivo effects of the recombinantly produced piiicp 4 . 1 protein : to investigate the effect of the recombinantly produced procollagen α 1 ( iii ) propeptides ( production described in burchardt , 1998 , and in the patent applications : an immunoassay for procollagen - iii - c - terminal propeptide ( wo 99 / 24835a2 and ep00988964a1 ), purification and renaturation described above in this patent application as an example ) on the formation of an experimentally induced liver fibrosis were carried out in the mouse ccl 4 model . groups of 8 mice were treated with ccl 4 only ( fibrosis control ), or additionally with piiicp4 . 1 protein solutions with concentrations of 50 μg / ml piiicp4 . 1 , of 150 μg / ml and of 500 μg / ml over a period of 14 days , respectively . in addition , on group was treated with buffer solution only ( intact control ). at the end of the treatment the dissolved piiicp in the infusion solution was not degraded in all cases . this was demonstrated with an sds page gel . in all animals , the relative collagen area with respect to the total area was determined morphometrically in liver sections , as well as the gidh activity in the serum and the mrna concentrations of selected transcripts by taqman analysis . the proteins were well tolerated by the animals over the studied time period in the concentrations used . there were no pathologic signs , furthermore an increased mortality did not occur . in all animals with ccl 4 application a reduction in body weight was observed in comparison with the untreated control animals at the end of the experiment ( table 2 ). however , when comparing between the fibrosis control and the piiicp groups significant differences were not observed . there was merely a tendency towards higher body weights in the animals receiving piiicp applications , independently of the received concentration . the relative liver weight was higher in all ccl 4 - treated groups than in the untreated intact control . there were no significant differences when the single treatment groups were compared to the fibrosis control ( table 2 ). when the total collagen deposition as determined by automatic analysis of the sirius red - stained areas is regarded , significant differences between the different groups of animals were revealed ( fig4 a ). after chronic treatment with i . p .- injected renatured piiicp4 . 1 solution a reduction in the total collagen area was measured in all treatment groups . in the treatment groups with the lowest piiicp dose ( 50 μg / ml ) the total collagen area was reduced significantly by 32 % in comparison with the fibrosis control ( p & lt ; 0 . 05 ). after a treatment with 150 μg / ml piiicp 4 . 1 the significant reduction was 44 % with respect to the fibrosis control ( p & lt ; 0 . 02 ). the treatment group with the highest protein concentration ( 500 μg / ml piiicp 4 . 1 ) exhibited marked variations of the measured total collagen area within the treatment group and showed a reduction of the total collagen area by 31 %. the level of significance ( p & lt ; 0 . 05 ) was not reached in comparison with the fibrosis control . the clinical parameter gidh activity was determined in the serum in parallel as a measure of the degree of cell damage and was markedly reduced in the groups that received additional piiicp4 . 1 protein solution in comparison with the fibrosis control ( table 2 ). after chronic treatment with 50 μg / ml piiicp4 . 1 gidh serum activity was 68 % of the activity in the fibrosis control , after 150 μg / ml piiicp it was at approximately 60 % of the fibrosis control and after 500 μg / ml it was at approximately 67 % of the fibrosis control . only at 150 μg / ml was the reduction significant in comparison with the fibrosis control ( p & lt ; 0 . 05 ). in the other two treatment groups the level of significance was not reached due to variations of the results from one animal to the other , respectively . after calibration based on hprt , differences between the intact control animals ( without ccl 4 application ) and the fibrosis control were observed with all transcripts ( collagen type i , collagen type iii , tenascin , pai - 1 , mmp - 1 , lysyl oxidase , and ctgf ). all examined transcripts were genes that participate in the synthesis of the extracellular matrix . consequently , the mrna concentrations were on the average by the factor of 6 to 10 higher in the fibrosis controls than in the intact controls . significant differences between those animals that were treated with piiicp4 . 1 in addition to the ccl 4 damage and the fibrosis control were measured for the ctgf transcript among all examined transcripts ( fig4 b ). at 50 μg / mipiiicp4 . 1 the difference was at approximately + 0 . 74 δ ct - units ( p & lt ; 0 . 04 ), at 150 μg / ml at approximately + 0 . 75 δ ct - units ( p & lt ; 0 . 05 ) and at 500 μg / ml piiicp4 . 1 at approximately + 1 . 41 δ ct - units ( p & lt ; 0 . 02 ). liver fibrosis model of the bile duct - ligated rat : in fastened female sprague - dawley rats the main bile duct was isolated after medial opening the upper abdomen medially during barbiturate anaesthesia . by means of an inserted catheter the bile duct system was occluded by the application of approximately 0 . 1 ml ethibloc per animal . the bile duct was subsequently ligated distally and proximally and dissected . intact control animals were also operated , the bile duct system was not occluded , however . the piiicp4 . 1 application ( production described in burchardt , 1998 , and in the patent applications : an immunoassay for procollagen - ill - c - terminal propeptide ( wo 99 / 24835a2 and ep00988964a1 ), purification and renaturation described above in this patent application as an example ) was performed by a permanent venous infusion via an implanted permanent catheter . the implantation of a femoral vein catheter was performed in parallel to the bile duct occlusion . for this purpose the skin was opened in the right inguinal region and the femoral vein was atraumatically isolated and fixated by two ligatures . after incision a venous catheter was inserted towards the heart and fixated . the catheter was subsequently directed towards the collar subcutaneously by means of a trocar and the surgical wound was closed by a skin suture . the venous catheter was connected to a rotation adapter by a necklace through a protective spiral . it was coupled to an infusion pump . for infection prophylaxis 0 . 1 ml of tardomycel were applied subcutaneously following the surgery . the initiation of the piiicp4 . 1 infusion at a concentration of 300 μg / ml took place 24 h after the surgery . the intact — and fibrosis controls received buffer control infusions . the infusion was performed at a rate of 0 . 2 ml per hour over a time period of seven days . the infusion solution was kept cool ( approximately 7 ° c .) over the entire time period of the experiment . the rats were kept in a round cage with free access to standard diet and water . the body weight of the animals was recorded at the beginning and at the end . at the end of the experiment the liver was portioned for subsequent experiments and immediately shock - frozen in liquid nitrogen and stored at − 80 ° c . until use . fixation of the tissue for immunohistochemistry : for immunohistochemical studies the tissues were fixated for 24 h in a 3 . 6 % formaldehyde solution ( v / v ). after washing with destined water the water was extracted with increasing concentrations of ethanol and the tissues were embedded in paraffin at 52 ° c . immunohistochemistry : 5 μm paraffin sections were deparaffinized . for this purpose the sections were immersed successively in xylol , pure ethanol , and in a concentration series of an ethanol - water mixture ( 90 % ( v / v ), 80 % ( v / v ) 70 % ( v / v )) and subsequently transferred into pure water . after a five minute treatment with 3 . 6 % ( v / v ) h 2 o 2 they were washed with destined h 2 o . subsequently they were washed for five minutes with pbs . blocking was performed for 20 minutes in a solution of 5 % ( w / v ) dry milk powder and in 1 % ( w / v ) bsa in pbs . after washing twice for three minutes in pbs the primary antibody ( monoclonal mouse anti - piiicp - antibody 48d19 ) was added at a concentration of 4 μg / ml in pbs and incubated for an hour at room temperature . after two further washing steps the next steps were performed according to the extravidin staining kit ( sigma aldrich ). the sections were incubated with biotinylated anti mouse igg &# 39 ; s in a 1 : 15 dilution in pbs with 1 % ( w / v ) for 20 minutes at room temperature . after two washing steps they were treated with a 1 : 15 dilution of extravidin peroxidase for 20 minutes at room temperature . this dilution was prepared using pbs with an addition of 1 % ( w / v ) bsa . following two washing steps the sections were developed for 10 minutes with the dab system ( 1 tablette per 5 ml of water , respectively ) ( sigma aldrich ). residual staining solution was removed with h 2 o dest . the counterstaining of the cell nuclei was performed using hematoxylin . the tissue sections were placed into acidic mayer &# 39 ; s hematoxylin ( 1 : 4 dilution in h 2 o dest . ), the stain was subsequently washed out with h 2 o dest . the sections were rinsed with tab water for 5 minutes to develop the bluish color of hematoxylin . after a washing step with h 2 o dest . the sections were dehydrated . using aqueous ethanol solutions of increasing concentrations the water was extracted ( 70 % ( v / v ), 80 % ( v / v ), 90 % ( v / v ), finally three times with pure ethanol ). the dehydrated sections were washed three times with xylol for 5 minutes and were embedded with the leica cv mount artificial resin . [ 0159 ] fig5 shows immunohistochemical studies with the anti - piiicp antibody 48d19 on representative sections from rat livers . a liver fibrosis was induced by a bile duct ligation . subsequently , a piiicp protein solution or a buffer control solution was infused for a period of 7 days through a permanent catheter . in the intact control , namely sham - operated animals infused with a buffer control solution , immunohistochemical staining with the piiicp antibody was hardly discernable ( fig5 a ). the fibrosis control revealed heavy damages to the liver ( fig5 c ). a massive proliferation of the bile ducts was observed in the damaged livers . in the area of the hepatic sinoids single cells , that proved positive for smooth muscle cell actin ( α - sma ) on control sections , were stained heavily . they were transformed hepatic stellate cells which were stained selectively . the hepatic sinoids were markedly reduced in their perfusion capacity . a staining of hepatocytes was not observed . on sections from animals with bile duct ligation and piiicp infusion a strong intracellular staining of hepatic stellate cells was also observed ( fig5 b ). in contrast to the fibrosis control , these cells showed additional intracellular staining in the shape of granula . this intracellular staining was in these cases also detected in hepatocytes with access to the sinoids . as far as can be seen , there was no specific immune reaction in the cell nucleus . the extent of fibrosis was less than in the fibrosis control . burchardt e r et al . monoclonal antibody and assay for detecting piiinp . wo 99 / 61477a2 . burchardt e r et al . an immunoassay for procollagen - iii - c - terminal propeptide . wo 99 / 24835a2 and ep00988964a1 . burchardt e r , schr ö der w , heke m , kohlmeyer j , neumann r , kroll w ( 1997 ) expression cloning of c - terminal procollagen ( iii ) propeptide and its use in a novel serum assay to monitor liver fibrogenesis . hepatology 26 : 487a . burchardt e r , heke m , kauschke s g , harjes p , kohlmeyer j , kroll w , schauer m , schroeder w , voelker m ( 1998 ) epitope - specific monoclonal antibodies against human c - terminal procollagen α 1 ( iii )- propeptide . matrix biology 17 : 673 - 677 . kauschke s g , knorr a , heke m , kohlmeyer j , schauer m , theiss g , waehler r , burchardt e r ( 1999 ) two assays for measuring fibrosis : rt - pcr of collagen alpha1 type iii is an early predictor of subsequent collagen deposition while a novel n - terminal procollagen ( iii ) propeptide assay reflects manifest fibrosis in ccl 4 - treated rats . analytical biochemistry 275 : 131 - 140 .
a medicament for treating or preventing fibrotic diseases contains an antifibrotic substance that is a peptide having antifibrotic activity and comprising at least one of an n - terminal procollagen propeptide and a c - terminal procollagen propeptide , or a fragment of the peptide defined having antifibrotic activity or a derivative of the peptide having antifibrotic activity . the antifibrotic substance is combined with a pharmaceutically tolerable carrier or dilutant .